MURRAY FRANK LLP Investigates Allos Therapeutics, Inc.
20 Julho 2011 - 10:55PM
Business Wire
MURRAY FRANK LLP is investigating breaches of fiduciary duties
by certain members of the Board of Directors of Allos Therapeutics,
Inc., (NASDAQ: ALTH) (“Allos” or the “Company”) regarding the
acquisition of the Company by AMAG Pharmaceuticals, Inc., (NASDAQ:
AMAG) (“AMAG”).
On July 20, 2011, Allos and AMAG announced that they had entered
into an agreement under which Allos would be acquired by AMAG in a
transaction valued at approximately $686 million. Pursuant to the
terms of the agreement, Allos shareholders will receive a fixed
ratio of 0.1282 shares of AMAG stock for each share of Allos stock
they own, a value of $2.44 per share of Allos common stock based on
the closing price of AMAG’s stock on July 19, 2011.
The investigation seeks to determine whether Allos’ Board of
Directors breached their fiduciary duties to Allos shareholders in
connection with their efforts to sell Allos to AMAG at an
inadequate price through an unfair process which significantly
undervalues the Company.
If you are a current investor in Allos who purchased Allos
shares before July 20, 2011, and you wish to discuss this
investigation or have any questions concerning this notice or your
rights or interests with respect to these matters, please contact
Katherine E. Smith at (800) 497-8076 or (212) 682-1818, or by email
at investigations@muarrayfrank.com.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Set 2024 até Out 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024
Notícias em tempo-real sobre Allos Therapeutics, Inc. (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Murray Frank LLP